Citius Pharmaceuticals CTXR 深 沪
已收盘 10-31 16:00:00 美东时间
1.58
+0.010
+0.64%
华盛通- 最 高1.59
- 今 开1.57
- 成交量 40.23万股
- 最 低 1.52
- 昨 收 1.57
- 总市值 1765.57万
- 52周最高 12.8375
- 市盈率 静 --
- 换手率 3.60%
- 52周最低 0.65
- 委 比 -34.03%
- 总股本 1117.45万
- 历史最高 137.25
- 量 比 0.70
- 振 幅 4.46%
- 历史最低 0.65
- 每 手 1
- 风险率 1.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Citius Pharmaceuticals Announces LYMPHIR Commercialization Plans
An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On October ...
10-24 05:29
Citius Pharmaceuticals Secures $6M in Stock Offering
Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On October 20, 2025...
10-22 05:00
Citius Oncology Announced It Has Finalized An Exclusive Agreement With EVERSANA To Support The Q4 2025 U.S. Commercialization Of LYMPHIR
EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapyCRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius
10-16 20:52
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why som...
10-08 22:58
Citius Oncology To Raise $9M In Registered Direct Offering Of 5.14M Shares At $1.75 Each, Plus Warrants For 5.14M Shares Exercisable At $1.84
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), a late-stage biopharmaceutical company developing and
09-09 20:47
Citius Oncology prices $9 million offering; shares down over 5%
Citius Oncology (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR), announced on Tuesday that it has entered into a securities purchase agreement with a single inst...
09-09 20:42
Citius Oncology Deploys AI Platform To Bolster Commercial Strategy Ahead Of LYMPHIR Launch
Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targeting and engagementCRANFORD, N.J., Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc.
08-22 20:49
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
08-14 00:16
Citius Pharma Q3 EPS $(0.80) Misses $(0.58) Estimate
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.58) by 36.75 percent. This is a 49.04 percent increase over losses of $(1.57) per share from
08-13 04:33
